Freeline Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Freeline Therapeutics Holdings's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 112.4% per year.
Key information
-6.3%
Earnings growth rate
43.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 112.4% |
| Return on equity | -166.2% |
| Net Margin | -8,027.7% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)
Jul 13
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Apr 11Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Dec 20We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate
Aug 30Freeline gains as NEJM publishes long-term data for hemophilia therapy
Jul 21Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?
May 05Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?
Jan 13Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky
Sep 30Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
Jun 03What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?
Feb 18
Revenue & Expenses BreakdownBeta
How Freeline Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -50 | 32 | 34 |
| 30 Jun 23 | 1 | -53 | 40 | 37 |
| 31 Mar 23 | 0 | -61 | 39 | 47 |
| 31 Dec 22 | 0 | -89 | 42 | 53 |
| 30 Sep 22 | 0 | -101 | 43 | 66 |
| 30 Jun 22 | 0 | -117 | 41 | 80 |
| 31 Mar 22 | 0 | -132 | 46 | 86 |
| 31 Dec 21 | 0 | -140 | 45 | 93 |
| 30 Sep 21 | 0 | -144 | 49 | 86 |
| 30 Jun 21 | 0 | -138 | 39 | 85 |
| 31 Mar 21 | 0 | -115 | 33 | 70 |
| 31 Dec 20 | 0 | -96 | 26 | 61 |
| 30 Sep 20 | 0 | -73 | 20 | 53 |
| 30 Jun 20 | 0 | -63 | 22 | 40 |
| 31 Mar 20 | 0 | -58 | 17 | 41 |
| 31 Dec 19 | 0 | -54 | 17 | 36 |
| 31 Dec 18 | 0 | -33 | 7 | 26 |
| 30 Sep 17 | 0 | -17 | 7 | 11 |
Quality Earnings: FRLN is currently unprofitable.
Growing Profit Margin: FRLN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FRLN is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.
Accelerating Growth: Unable to compare FRLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FRLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.1%).
Return on Equity
High ROE: FRLN has a negative Return on Equity (-166.22%), as it is currently unprofitable.